Author

Marko Brinar

PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE
PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE

PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE
PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSAL HEALING RATES IN CROHN'S DISEASE

Marko Brinar  et al.

AGE RELATED PREVALENCE OF SEXUAL AND ERECTYLE DYSFUNCTION AND LOW QUALITY OF LIVE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
AGE RELATED PREVALENCE OF SEXUAL AND ERECTYLE DYSFUNCTION AND LOW QUALITY OF LIVE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marko Brinar  et al.

EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER
EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER

Marko Brinar  et al.

FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE
FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE

Marko Brinar  et al.

ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE
ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE

Marko Brinar  et al.

BIOMARKERS OF ELASTIN DEGRADATION DIFFERENTIATE BETWEEN CLINICALLY INACTIVE AND ACTIVE DISEASE IN UC PATIENTS
BIOMARKERS OF ELASTIN DEGRADATION DIFFERENTIATE BETWEEN CLINICALLY INACTIVE AND ACTIVE DISEASE IN UC PATIENTS

Marko Brinar  et al.

BIOMARKERS OF ELASTIN DEGRADATION IS ASSOCIATED WITH CLINICAL AND BIOCHEMICALLY ACTIVE DISEASE IN CROHN'S DISEASE
BIOMARKERS OF ELASTIN DEGRADATION IS ASSOCIATED WITH CLINICAL AND BIOCHEMICALLY ACTIVE DISEASE IN CROHN'S DISEASE

Marko Brinar  et al.

SEROLOGICAL MARKERS OF EXTRACELLULAR MATRIX REMODELING REFLECTS ENDOSCOPIC DISEASE ACTIVITY AND SEVERITY IN CROHN'S DISEASE AND ULCERATIVE COLITIS
SEROLOGICAL MARKERS OF EXTRACELLULAR MATRIX REMODELING REFLECTS ENDOSCOPIC DISEASE ACTIVITY AND SEVERITY IN CROHN'S DISEASE AND ULCERATIVE COLITIS

Marko Brinar  et al.

ARTIFICIAL INTELLIGENCE: A NEW TOOL IN ENDOSCOPIC SURVEILLANCE IN INFLAMMATORY BOWEL DISEASE PATIENTS
ARTIFICIAL INTELLIGENCE: A NEW TOOL IN ENDOSCOPIC SURVEILLANCE IN INFLAMMATORY BOWEL DISEASE PATIENTS

Marko Brinar  et al.

NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD
NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD

Marko Brinar  et al.

ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER
ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER

Marko Brinar  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Marko Brinar  et al.

Item 1 - 13 / 13
1